Aripiprazole & Fluoxetine Interaction

Fluoxetine is a potent inhibitor of CYP2D6, the primary enzyme responsible for aripiprazole metabolism, and concomitant use can approximately double aripiprazole plasma concentrations ^[1][2]. This pharmacokinetic interaction is clinically significant and the aripiprazole prescribing information specifically recommends halving the aripiprazole dose when co-administered with strong CYP2D6 inhibitors like fluoxetine ^[1].

The combination is clinically common: aripiprazole is FDA-approved as an adjunct to antidepressants for treatment-resistant depression, and fluoxetine is one of the most prescribed SSRIs ^[1][2]. Therefore, this interaction is frequently encountered in practice and must be proactively managed rather than avoided. The classification as major reflects the magnitude of the pharmacokinetic change (2-fold increase in aripiprazole exposure) and the clinical consequences if the interaction is not recognized ^[1].

Without dose adjustment, elevated aripiprazole levels can manifest as akathisia (restlessness), somnolence, nausea, orthostatic hypotension, and rarely extrapyramidal symptoms (EPS) or QT prolongation ^[1][3].

Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4 to its active metabolite dehydro-aripiprazole, which has similar pharmacologic activity ^[1]. CYP2D6 accounts for approximately 60% of aripiprazole elimination, making it highly susceptible to CYP2D6 inhibition ^[1]. Fluoxetine and its long-lived active metabolite norfluoxetine (half-life 4-16 days) are potent CYP2D6 inhibitors that significantly reduce aripiprazole clearance ^[2].

Pharmacodynamic studies show that when aripiprazole exposure doubles, the degree of D2 receptor occupancy increases from approximately 60-70% (therapeutic range) toward 80-85% (associated with increased EPS risk) ^[1][3]. Aripiprazole is a partial D2 agonist, meaning its pharmacology shifts from functional agonism to functional antagonism at higher occupancy levels, which can paradoxically worsen akathisia and EPS at elevated concentrations ^[1].

The interaction is further complicated in CYP2D6 poor metabolizers (6-10% of Caucasians), who already have reduced aripiprazole clearance. In these patients, adding fluoxetine creates a phenocopy of absent CYP2D6 function combined with actual poor metabolizer status, potentially producing aripiprazole levels 3-4 times normal ^[1].

This is classified as a major interaction due to the substantial pharmacokinetic magnitude and the clinical consequences of undiscovered elevated aripiprazole levels ^[1]. Without dose adjustment, patients commonly experience akathisia (inner restlessness, need to move) in 15-25% of cases, somnolence in 20-30%, and nausea in 10-15% ^[1][3]. EPS (tremor, rigidity, dystonia) and orthostatic hypotension are less common but can be distressing and potentially dangerous, particularly in elderly patients.

The FDA prescribing information for aripiprazole provides specific dose-adjustment guidance: reduce the aripiprazole dose to 50% of the usual dose when co-administered with strong CYP2D6 inhibitors ^[1]. Failure to make this adjustment is a recognized prescribing error and a common cause of aripiprazole adverse effects in clinical practice ^[3][4].

The aripiprazole dose should be reduced by approximately 50% when initiating concomitant fluoxetine ^[1]. For example, if the patient is on aripiprazole 10 mg/day, reduce to 5 mg/day. If adding aripiprazole to existing fluoxetine therapy, start at half the usual initial dose (e.g., 2.5 mg instead of 5 mg for augmentation of depression) ^[1].

When fluoxetine is discontinued, the aripiprazole dose should be gradually increased back to the original dose over 4-6 weeks (reflecting the long washout of norfluoxetine) ^[2]. Patients should be warned about potential symptoms of elevated aripiprazole levels: restlessness, tremor, excessive drowsiness, dizziness on standing, and nausea ^[1][3]. If these symptoms develop, hold aripiprazole and contact the prescriber for dose adjustment ^[1].

After initiating the combination or any dose change, assess for akathisia (Barnes Akathisia Rating Scale if available), EPS (Simpson-Angus Scale), and orthostatic vital signs at 1-2 weeks and then monthly for 3 months ^[1][3]. Weight and metabolic parameters per standard atypical antipsychotic monitoring: fasting glucose and lipids at baseline, 3 months, and annually ^[1]. Prolactin level if symptoms suggest hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), though aripiprazole typically lowers prolactin due to its D2 partial agonism ^[1].

CYP2D6 genotyping can be helpful if the patient experiences unexpected adverse effects despite dose adjustment, as poor metabolizers require even lower aripiprazole doses ^[1].

For antidepressant augmentation: brexpiprazole (structurally similar to aripiprazole but with less akathisia risk) is an alternative partial D2 agonist, though it is also a CYP2D6 substrate with similar interaction potential. Quetiapine is FDA-approved for adjunctive depression treatment and is metabolized primarily by CYP3A4 rather than CYP2D6, avoiding the fluoxetine interaction. Switching from fluoxetine to sertraline or escitalopram (weaker CYP2D6 inhibitors) reduces the pharmacokinetic interaction with aripiprazole ^[2][4].